ClinicalTrials.gg
Active, not recruitingNCT04985643LEADERUpdated May 22, 2026

A Study of Real Life Treatment for Multiple Myeloma (MM)

An observational study in Multiple Myeloma, sponsored by Takeda. Active, not recruiting at 24 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Takeda · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
357
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Multiple Myeloma by Takeda — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Myeloma · Takeda.

Enrollment
5th of 13
357 · median 295
Started
2022
with 1 other
Observational
13 of 54
1 open now
Registered
49th of 54
by date

Among the 54 studies in Multiple Myeloma by Takeda, this one is the 5th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2022, is one of 13 observational ones, and was the 49th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

2 of the 54 studies in Multiple Myeloma by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Multiple Myeloma by Takeda, or all of them as a file.
02

Study summary

The main aim of this study is to learn how long it takes for people with MM to have a relapse after their first treatment. Not all participants will have a relapse during the study.

Participants will visit their clinic every 3 months and be treated according to their clinic's standard practice.

The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.

Read the detailed description

This is a non-interventional, prospective study of participants with MM relapses. This study will assess the low detection rate of biochemical relapses which will improve routine clinical practices and management of participants with MM in real world practice.

The study will enroll approximately 350 participants. The data will be collected both prospectively and/or retrospectively at the specialized care (hematology) and will be recorded into electronic case report forms (e-CRFs) of the electronic data capture (EDC) system. All the participants will be assigned to a single observational cohort:

  • Participants With MM

This multi-center study will be conducted in the Russian Federation. The overall duration of the study will be approximately 4 years. The overall time for treatment and follow-up period will be approximately 2.5 years for each participant.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will enroll participants who have a confirmed diagnosis of MM in clinical sites located in the Russian Federation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. With newly diagnosed multiple myeloma (NDMM) eligible and non-eligible for a high-dose therapy and stem cell transplantation (HDT-ASCT) who have had a response (defined as CR, VGPR, or PR) to the ongoing SoC induction () therapy that has been started within 3 months before the inclusion.
  2. (ECOG) performance status of 0 to 2 at the time of inclusion.

Exclusion criteria

Exclusion Criteria:

  1. With NDMM eligible and non-eligible for a HDT- who have had SD or PD to the ongoing standard of care (SoC) induction () therapy that has been started within 3 months before the inclusion.
  2. Current, previous (within the last year) or planned (for the next 15-20 months) participation in interventional clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
357 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants With MM

    Participants diagnosed with MM (complete response \[CR\], very good partial response \[VGPR\] and partial response \[PR\]) and who have received one prior first line treatment within 3 months preceding the enrollment, will be observed retrospectively and medical data will be monitored and collected prospectively every 3 months until the second biochemical and symptomatic relapse is identified.

06

What researchers measure

Primary outcomes

  1. Median Time From the Start of First Line Therapy of Participants With MM to First Biochemical Relapse of MM

    According to the International Myeloma Working Group (IMWG), biochemical relapse is diagnosed in participants with relapsing MM based on the following criteria: increase in serum paraprotein by at least 25 percent (%) of nadir (absolute increase should be at least greater than or equal to \[\>=\] 0.5 gram per liter \[g/L\]), increase in urine paraprotein by at least 25% (absolute increase of at least \>=200 milligram per 24 hours \[mg/24 h\]), more than 25% increase in the difference between involved and non-involved free light chains (FLC) with abnormal FLC ratio and absolute increase of at least greater than (\>) 10 milligram per deciliter (mg/dL), increase in plasmacyte infiltration by least \>=10% in participants with non-secretory MM.

    Time frame: From the start of the first line therapy until first biochemical relapse (up to approximately 4 years)

Secondary outcomes

  1. Median Time From the Start of First Line Therapy of Participants With MM to First Biochemical Relapse of MM in the Determined Subgroups

    As per IMWG, biochemical relapse diagnosed with relapsing MM on following criteria: increase in serum paraprotein by at least 25% of nadir (absolute increase should be at least \>=0.5 g/L, increase in urine paraprotein by at least 25% (absolute increase of at least \>=200 mg/24 h, \>25% increase in difference between involved and non-involved FLC with abnormal FLC ratio and absolute increase of at least \>10 mg/dL, increase in plasmacyte infiltration by least \>=10% with non-secretory MM. Subgroups for analysis: MM International Staging System (ISS) stages: I, II, III; Myeloma frailty score (MFS): 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk;Best response during 1st line treatment: a PR a CR or VGPR;Performance status: Eastern Cooperative Oncology Group (ECOG) = 0-1 vs ECOG = 2;Autologous Stem Cell Transplant (ASCT) vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line

    Time frame: From the start of the first line therapy until first biochemical relapse (up to approximately 4 years)

  2. Median Time From the Start of First Line Therapy of Participants With MM

    Clinical relapse is confirmed when one or more of the following criteria (CRAB-criteria: MM-associated symptoms: hypercalcemia, renal failure, anemia, bone disease criteria). Hypercalcemia (\>2.75 millimole per liter \[mmol/L\] or \>11.5 mg/dL); renal failure: serum creatinine level \>2 mg/dL (\>173 mmol/L); anemia: normochromic normocytic anemia with hemoglobin level by less than (\<) 2 g/dL (20 milligram per liter \[mg/L\]) less than the lower limit of the normal level or hemoglobin level \<10 g/dL (\<100 gram per liter \[g/L\]); bone lesions (lytic lesions, severe osteopenia, compression fractures). Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR\* a CR8 or VGPR9; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers, Maintenance therapy; Treatment regimens of 1st line.

    Time frame: From the start of the first line therapy until first symptomatic relapse (up to approximately 4 years)

  3. Median Time From the Start of Second Line Therapy of Participants With MM to Second Biochemical Relapse of MM

    According to IMWG, biochemical relapse is diagnosed in participants with relapsing MM based on following criteria: increase in serum paraprotein by at least 25% of nadir (absolute increase should be at least \>=0.5 g/L), increase in urine paraprotein by at least 25% (absolute increase of at least \>=200 mg/24 h), more than 25% increase in difference between involved and non-involved FLC with abnormal FLC ratio and absolute increase of at least \>10 mg/dL, increase in plasmacyte infiltration by least \>=10% in participants with non-secretory MM. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line;Therapeutic regimens of 2nd line (Rd, VRD, KRd, IxaRd, DaraRd, EloRd, other).

    Time frame: From the start of the second line therapy until second biochemical relapse (up to approximately 4 years)

  4. Median Time From the Start of Second Line Therapy of Participants With MM to Second Symptomatic Relapse of MM

    Clinical relapse is confirmed when one or more of the following criteria (CRAB-criteria: MM-associated symptoms, including hypercalcemia, renal failure, anemia, bone disease criteria) are found. Hypercalcemia (\>2.75 mmol/L or \>11.5 mg/dL), renal failure: serum creatinine level \>2 mg/dL (\>173 mmol/L), anemia: normochromic normocytic anemia with hemoglobin level by \<2 g/dL (20 mg/L) less than the lower limit of the normal level or hemoglobin level \<10 g/dL (\<100 g/L), bone lesions (lytic lesions, severe osteopenia, compression fractures). Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line;Therapeutic regimens of 2nd line (Rd, VRD, KRd, IxaRd, DaraRd, EloRd, other).

    Time frame: From the start of the second line therapy until second symptomatic relapse (up to approximately 4 years)

  5. PFS1L: Progression-free Survival (PFS) From the Start of first Line Therapy to the First Biochemical Relapse

    PFS1L:interval from start of 1st line therapy to 1st significant biochemical relapse. As per IMWG, biochemical relapse diagnosed in participants with relapsing MM on following criteria: increase in serum paraprotein by at least 25% of nadir (absolute increase should be at least \>=0.5 g/L, increase in urine paraprotein by at least 25% (absolute increase of at least \>=200 mg/24 h, \>25% increase in difference between involved and non-involved FLC with abnormal FLC ratio and absolute increase of at least \>10 mg/dL, increase in plasmacyte infiltration by least \>=10% with non-secretory MM. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line.

    Time frame: From the start of the first line therapy until first significant biochemical relapse or until the disease progression or death due to any reason whichever occurs first (up to approximately 4 years)

  6. PFS2L: Progression-free Survival From the Start of Second Line Therapy to the Second Biochemical Relapse

    PFS2L: interval from start of 2nd line therapy to 2nd significant biochemical relapse. As per IMWG, biochemical relapse diagnosed in participants with relapsing MM on following criteria: increase in serum paraprotein by at least 25% of nadir (absolute increase should be at least \>=0.5 g/L, increase in urine paraprotein by at least 25% (absolute increase of at least \>=200 mg/24 h, \>25% increase in difference between involved and non-involved FLC with abnormal FLC ratio and absolute increase of at least \>10 mg/dL, increase in plasmacyte infiltration by least \>=10% with non-secretory MM. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line;Therapeutic regimens of 2nd line (Rd, VRD, KRd, IxaRd, DaraRd, EloRd, other).

    Time frame: From the start of the second line therapy until second significant biochemical relapse or until the disease progression or death due to any reason whichever occurs first (up to approximately 4 years)

  7. DOT1: Duration of the First Line Therapy

    DOT1 is defined as time from initiation of the first drug to discontinuation of the last drug in the frame of first line of therapy. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line.

    Time frame: From initiation of the first drug to discontinuation of the last drug in the frame of first line therapy (approximately 4 years)

  8. DOMT1: Duration of 1st Line Maintenance Therapy

    DOMT1 is defined as the treatment duration of first line maintenance therapy. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line.

    Time frame: From initiation of the first line maintenance therapy to discontinuation of the last drug in the frame of first line maintenance therapy (approximately 4 years)

  9. DOT2: Duration of the Second Line Therapy

    DOT2 is defined as time from initiation of the first drug to discontinuation of the last drug in the frame of second line of therapy. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line;Therapeutic regimens of 2nd line (Rd, VRD, KRd, IxaRd, DaraRd, EloRd, other).

    Time frame: From initiation of the first drug to discontinuation of the last drug in the frame of second line therapy (approximately 4 years)

  10. PR1L: Percentage of Participants With Partial Response After First Line Therapy

    PR is defined as \>=50% reduction of serum M protein and \>=90% or \<200 mg reduction urinary M protein in 24-hour, or \>50% decrease in difference between involved and uninvolved FLC levels, or \>50% reduction in bone marrow plasma cells, if bone marrow plasma cells \>30% and \>50% reduction in size of soft tissue plasmacytomas at baseline. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line.

    Time frame: From the end of the first line therapy up to approximately 4 years

  11. VGPR1L: Percentage of Participants With VGPR After First Line Therapy

    VGPR defined as \>90% reduction (\<100 mg/24-hour) in serum M-protein + urine M-protein detectable by immunofixation but not on electrophoresis. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line.

    Time frame: From the end of the first line therapy up to approximately 4 years

  12. CR1L: Percentage of Participants With Complete Response After First Line Therapy

    Complete response is defined as \>5% plasma cells in myelogram with absence of paraprotein in serum and urine according to immunofixation. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line.

    Time frame: From the end of the first line therapy up to approximately 4 years

  13. ORR2L: Percentage of Participants With Objective Response Rate After the Second Line Therapy

    ORR2L: percentage of participants with CR, VGPR or PR assessed by IMWG to 2nd line therapy. Per IMWG criteria, CR: \>5% plasma cells in myelogram with absence of paraprotein in serum and urine according to immunofixation; VGPR: \>90% reduction (\<100 mg/24-h) in serum M-protein + urine M-protein detectable by immunofixation but not on electrophoresis; PR: \>=50% reduction of serum M protein and \>=90% or \<200 mg reduction urinary M protein in 24-hour, or \>50% decrease in difference between involved and uninvolved FLC levels, or \>50% reduction in bone marrow plasma cells, if bone marrow plasma cells \>30% and \>50% reduction in size of soft tissue plasmacytomas at baseline. Subgroups for analysis: MM ISS stages: I, II, Ill; MFS: 0 and 1 vs 2 and more;Cytogenetic high-risk vs standard risk; Best response during 1st line treatment;ECOG = 0-1 vs 2, ASCT vs non-ASCT receivers;Maintenance therapy;1st and 2nd line Treatment regimens.

    Time frame: From the end of the second line therapy up to approximately 4 years

  14. SD2L: Percentage of Participants With Stable Disease After the Second Line Therapy

    Stable disease (SD) is defined as any state that does not meet PR, VGPR, CR, or progressive disease (PD) criteria. Subgroups for analysis: MM ISS stages: I, II, III; MFS: 0 and 1 vs 2 and more;Cytogenetic risk: high-risk vs standard risk; Best response during 1st line treatment: a PR a CR or VGPR; Performance status: ECOG = 0-1 vs ECOG = 2, ASCT vs non-ASCT receivers; Maintenance therapy; Treatment regimens of 1st line;Therapeutic regimens of 2nd line (Rd, VRD, KRd, IxaRd, DaraRd, EloRd, other).

    Time frame: From the end of second line therapy up to approximately 4 years

  15. PD2L: Percentage of Participants With Progressive Disease After Second Line Therapy

    PD: increase in M-gradient by \>=25% of least achieved serum (increase by \>=5 g/L), urine (increase by \>=200 mg/24 h) levels. With disease, "unmeasurable" by standard immunochemistry, but "measurable" by FLC level, progression: stated with increase in difference between involved and non-involved FLC by 100 mg/L. Progression: increase in bone marrow plasmatic cells level (absolute count-not less than by 10%), occurrence of new bone lesions or increase in size of previously detected ones, occurrence of new soft tissue plasmocytomas or increase in its size, hypercalcemia (corrected serum calcium level \>11.5 mg/dL or 2.65 mmol/L) may be related to proliferation. Subgroups for analysis: MM ISS stages: I, II, Ill; MFS: 0 and 1 vs 2 and more;Cytogenetic high-risk vs standard risk; Best response during 1st line treatment;ECOG = 0-1 vs 2, ASCT vs non-ASCT receivers;Maintenance therapy;1st and 2nd line Treatment regimens.

    Time frame: From the end of second line therapy up to approximately 4 years

  16. Percentage of Participants With High-risk Cytogenetic Disorders at the Time of the First Symptomatic Relapse

    High-risk Cytogenetic Disorder is defined as risk according to cytogenetic profile at relapse (t\[4;14\], del (17p), amp (1q21), hypodiploidy) at the time of the first symptomatic relapse.

    Time frame: From the start of the first line therapy until first symptomatic relapse (up to approximately 4 years)

  17. Percentage of Participants With High β2-microglobulin (ß2M) or Low Albumin Levels at the Time of the First and Second Symptomatic Relapse

    ß2M levels is defined as \>5.5 mg/L and low albumin levels is defined as \<3.5 g/dL at first symptomatic relapse.

    Time frame: From the start of the first line therapy until first symptomatic relapse (for first symptomatic relapse) and until second symptomatic relapse (for second symptomatic relapse) (up to approximately 4 years)

  18. Percentage of Participants With Extramedullary Lesions at the Time of the First and Second Symptomatic Relapse

    Time frame: From the start of the first line therapy until first symptomatic relapse (for first symptomatic relapse) and until second symptomatic relapse (for second symptomatic relapse) (up to approximately 4 years)

  19. Percentage of Participants With Lactate Dehydrogenase (LDH) Levels Above Normal at the Time of the First and Second Symptomatic Relapse

    Time frame: From the start of the first line therapy until first symptomatic relapse (for first symptomatic relapse) and until second symptomatic relapse (for second symptomatic relapse) (up to approximately 4 years)

  20. Percentage of Participants With Short Duration of Response or PD During Therapy at the Time of the First and Second Symptomatic Relapse

    PD is defined as increase in M-gradient by \>=25% of least achieved serum (increase by \>=5 g/L), urine (increase by \>=200 mg/24 h) levels. For participants with disease, "unmeasurable" by standard immunochemistry, but "measurable" by FLC level, progression is stated with increase in difference between involved and non-involved FLC by 100 mg/L. Progression is also indicated by increase in bone marrow plasmatic cells level (absolute count - not less than by 10%), occurrence of new bone lesions or increase in size of previously detected ones, occurrence of new soft tissue plasmocytomas or increase in it's size, hypercalcemia (corrected serum calcium level \>11.5 mg/dL or 2.65 mmol/L) that may be related to proliferation. Short duration of response \<6 months.

    Time frame: From the start of the first line therapy until first symptomatic relapse (for first symptomatic relapse) and until second symptomatic relapse (for second symptomatic relapse) (up to approximately 4 years)

  21. Percentage of Participants With Circulating Plasma Cells at the Time of the First and Second Symptomatic Relapse

    Time frame: From the start of the first line therapy until first symptomatic relapse (for first symptomatic relapse) and until second symptomatic relapse (for second symptomatic relapse) (up to approximately 4 years)

  22. Percentage of Participants With ISS stages II/III at the Time of the First and Second Symptomatic Relapse

    ISS is a measuring scale having three stages Stage I:low risk, β2-Microglobulin \<3.5mg/L and albumin \>=3.5g/dL, Stage II: not stage I or III, Stage III: high risk,β2-Microglobulin \>=5.5mg/L.

    Time frame: From the start of the first line therapy until first symptomatic relapse (for first symptomatic relapse) and until second symptomatic relapse (for second symptomatic relapse) (up to approximately 4 years)

  23. Percentage of Participants With Isotypic Transformation at the Time of the First and Second Symptomatic Relapse

    Isotypic Transformation is defined as change in the type of secretion of light chains, hypersecretory disease.

    Time frame: From the start of the first line therapy until first symptomatic relapse (for first symptomatic relapse) and until second symptomatic relapse (for second symptomatic relapse) (up to approximately 4 years)

  24. Percentage of Participants With First and Second Symptomatic Relapse who Have Aggressive Clinical Disease Manifestations

    Aggressive clinical disease manifestations include the rapid development/quick start of symptoms manifestations, an advanced diseases stages based on the laboratory results, radiography or pathomorphological examinations, organ failure (disease-related organ disorder).

    Time frame: From the start of the first line therapy until first symptomatic relapse (for first symptomatic relapse) and until second symptomatic relapse (for second symptomatic relapse) (up to approximately 4 years)

  25. Number of Participants Reporting One or More Adverse Events (AEs) With First Line Therapy

    Time frame: Up to approximately 4 years

  26. Number of Participants Reporting One or More AEs With Second Line Therapy

    Time frame: Up to approximately 4 years

07

Study locations

24 sites
  • Altai Regional Clinical Hospital
    Barnaul, Altayskiy Kray 656024, Russia
  • Kaluga Regional Clinical Hospital
    Kaluga, Central Federal District 248007, Russia
  • Smolensk Clinical Hospital of Russian Railways-Medicine
    Smolensk, Central Federal District 214025, Russia
  • City Clinical Hospital No. 1 named after prof. S.I.Sergeev
    Khabarovsk, Far Eastern Federal District 680009, Russia
  • Kirov Research Institute of Hematology and Blood Transfusion
    Kirov, Kirov Oblast 610027, Russia
  • GUZ "Lipetsk City Hospital No. 3" Free Falcon "
    Lipetsk, Lipetsk Oblast 398007, Russia
  • National Research Center of Hematology of the Ministry of Health
    Moscow, Moscow Oblast 125167, Russia
  • Herzen Moscow Scientific Research Oncological Institute
    Moscow, Moscow Oblast 125284, Russia
  • Moscow Regional Research Clinical Institute n.a. M.F. Vladimirsky
    Moscow, Moscow Oblast 129110, Russia
  • BaltikMed Clinic
    Kaliningrad, Northwestern Federal District 238022, Russia
  • Vologda Regional Clinical Hospital
    Vologda, Northwestern Federal District 160002, Russia
  • Novosibirsk State Medical University, Department of Therapy, Hematology and Transfusiology based on City Clinical Hospital No. 2
    Novosibirsk, Novosibirsk Oblast 630051, Russia
  • Orenburgskaya Regional Clinical Hospital n.a. V.I. Voinova
    Orenburg, Orenburgskaya District 460018, Russia
  • Republican hospital named after V.A.Baranov
    Petrozavodsk, Republic of Karelia 185019, Russia
  • Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
    Kazan', Republic Tatarstan 420064, Russia
  • City Clinical Hospital No. 31
    Saint Petersburg, Sankt-Peterburg 197110, Russia
  • Razumovskiy Saratov State Medical University, University Clinical
    Saratov, Saratov Oblast 410028, Russia
  • Tomsk Regional Clinical Hospital
    Tomsk, Siberian Federal District 634063, Russia
  • District Clinical Hospital
    Khanty-Mansiysk, Tyumen Oblast 628012, Russia
  • Surgut Regional Clinical Hospital
    Surgut, Tyumen Oblast 628408, Russia
  • Ulyanovsk Regional Clinical Hospital
    Ulyanovsk, Ulyanovsk Oblast 432017, Russia
  • City Clinical Hospital No. 12
    Nizhny Novgorod, Volga Federal District 603003, Russia
  • Clinic Akademicheskaya LLC
    Volgograd, Volgogradskaya District 400001, Russia
  • Republican Clinical Hospital named after G.G. Kuvatov
    Ufa, 450005, Russia
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jun 2027, 64 months after the start.

Of 66 industry-sponsored observational studies under Multiple Myeloma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 70. This study's planned 64 months is above that.

Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 2, 2021
StartActual
Feb 18, 2022
Primary completionEst.
Jun 20, 2027
CompletionEst.
Jun 20, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04985643
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Feb 18, 2022
Primary completion
Jun 20, 2027 (estimated)
Completion
Jun 20, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion